Recent Company News

• 04:19 PM ET Aug 12, 2025
  

  Adagene reports H1 EPS ($0.23) vs year-ago ($0.31) ($1.91, 0.00)

• 06:27 AM ET Aug 06, 2025
  

  Leerink Partners initiates ADAG, XLO

• 07:04 AM ET Jul 15, 2025
  

  Adagene announces regulatory update on clinical development plan for muzastotug in MSS CRC following Type B meeting with FDA ($1.83, 0.00)

• 07:04 AM ET Jul 08, 2025
  

  Adagene and ConjugateBio partner to develop novel antibody drug conjugate ($1.95, 0.00)

• 05:40 PM ET Jul 01, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:58 AM ET Jul 01, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:19 AM ET Jul 01, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:06 AM ET Jul 01, 2025
  

  Adagene announces up to $25M strategic investment from Sanofi ($1.95, 0.00)

• 05:07 PM ET May 30, 2025
  

  Adagene enters ADS sales agreement for up to $100M with Leerink - 424B5 ($1.94, 0.00)

• 05:08 PM ET May 22, 2025
  

  Adagene announces presentation of updated data from phase 1B/2 study of Muzastotug (ADG126) in combination with KEYTRUDA ($1.63, 0.00)